Jennifer Diamond, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz Medical Campus

Jennifer Diamond, University of Colorado Anschutz Medical Campus

Caption

University of Colorado Cancer Center investigator, Jennifer Diamond, MD, and colleagues report promising phase I results of alisertib with TAK-228 against solid tumors including triple-negative breast cancer.

Credit

University of Colorado Cancer Center

Usage Restrictions

with attribution

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.